Compare IDEXX Laboratories, Inc. (IDXX) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Vanguard International High Dividend Yield ETF — how do they compare? IDEXX Laboratories, Inc. trades at $571 (market cap $46.22B), while Vanguard International High Dividend Yield ETF trades at $104.78. The key difference: Vanguard International High Dividend Yield ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | VYMI | |
|---|---|---|
Market Cap | $46.22B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $766.68 | $105.05 |
52-Week Low | $526.44 | $82.92 |
Enterprise Value | $47.12B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
VYMI, the Vanguard International High Dividend Yield ETF, trades at $104.59 with a neutral daily change. Technical indicators show a bullish trend from moving averages, though oscillators are neutral to slightly overbought. The fund has gained attention for its income appeal, with a 3.4% dividend yield and strong performance, including a 55% total return since prior coverage, as noted by Seeking Alpha on 2026-08-02. Recent institutional buying, such as by Barry Investment Advisors on 2026-08-10, underscores confidence.
The outlook is positive, driven by global diversification and high dividend growth, with Vanguard projecting international stocks to outperform U.S. equities over the next decade. Risks include currency fluctuations and economic volatility in international markets. Analyst sentiment is bullish, supported by the fund's defensive yield and institutional inflows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
